Kiora Pharmaceuticals, Inc.
Kiora Pharmaceuticals, Inc. (KPRX) Revenue
Annual & quarterly revenue history · segment & region breakdown
KPRX · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsKiora Pharmaceuticals, Inc. trailing twelve-month (TTM) revenue is $0.00B, a decrease of 100.00% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2012 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | -$0.02B | -100.00% |
| 2024-12-31 | $0.02B | +$0.02B | — |
| 2023-12-31 | $0.00B | +$0.00B | — |
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | -$0.00B | -100.00% |
| 2020-12-31 | $0.00B | -$0.00B | -99.55% |
| 2019-12-31 | $0.00B | +$0.00B | +62.54% |
| 2018-12-31 | $0.00B | +$0.00B | +305.51% |
| 2017-12-31 | $0.00B | -$0.00B | -39.11% |
| 2016-12-31 | $0.00B | +$0.00B | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Kiora Pharmaceuticals, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Kiora Pharmaceuticals, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Kiora Pharmaceuticals, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
KPRX revenue · 4 questionsKPRX's trailing twelve-month (TTM) revenue is $0.00B. That is a decrease of 100.00% year-over-year from $0.00B in FY2025.
▸ Source: FMP · Kiora Pharmaceuticals, Inc. SEC filings · GAAP · Kiora Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026